Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)

Mylan (MYL) PT Raised to $44 at BofA/Merrill Lynch Following Generic Estrace Cream Approval

January 4, 2018 8:08 AM EST

BofA/Merrill Lynch raised its price target on Mylan (NASDAQ: MYL) to $44.00 (from $41.00) while maintaining a Neutral rating following the recent approval of generic Estrace Cream, Allergans womens health brand with $375m net sales. MYL recently launched (12/29) g-Estrace followed by an authorized... More